Celon Pharma (FRA:8RP) E10: €0.05 (As of Mar. 2026)


FRA:8RP Celon Pharma SA FRA:8RP
13 GF Score
Price €4.39
GF Value €5.11
! 3 Warning Signs
View Full Analysis

What is Celon Pharma E10?

Celon Pharma FRA:8RP +0.11% 13 E10 is €0.05 as of Mar. 2026. GuruFocus rates FRA:8RP with a GF Score™ of 13/100 and a GF Value™ of €5.11. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Celon Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was €0.708. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €0.05 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-05), Celon Pharma's current stock price is €4.39. Celon Pharma's E10 for the quarter that ended in Mar. 2026 was €0.05. Celon Pharma's Shiller PE Ratio of today is 87.80.

During the past 11 years, the highest Shiller PE Ratio of Celon Pharma was 2280.00. The lowest was 94.19. And the median was 101.43.


Celon Pharma  (FRA:8RP) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Celon Pharma's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=4.39/0.05
=87.80

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Shiller P/E Ratio of Celon Pharma was 2280.00. The lowest was 94.19. And the median was 101.43.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Celon Pharma E10 Related Terms


Celon Pharma E10 Historical Data

* Premium members only.

The historical data trend for Celon Pharma's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celon Pharma E10 Chart

Celon Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.01

Celon Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.01 0.05

FRA:8RP vs ZTS, UTHR, VTRS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Celon Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celon Pharma Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celon Pharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Celon Pharma's Shiller PE Ratio falls into.


FRA:8RP
13GF Score
Celon Pharma SA FRA:8RP
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Celon Pharma E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Celon Pharma's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.708/163.0700*163.0700
=0.708

Current CPI (Mar. 2026) = 163.0700.

Celon Pharma Quarterly Data

per share eps CPI Adj_EPS
201606 0.037 99.552 0.061
201609 0.037 99.064 0.061
201612 0.014 100.366 0.023
201703 0.025 101.018 0.040
201706 0.044 101.180 0.071
201709 0.025 101.343 0.040
201712 0.032 102.564 0.051
201803 0.039 102.564 0.062
201806 0.039 103.378 0.062
201809 0.043 103.378 0.068
201812 0.032 103.785 0.050
201903 0.032 104.274 0.050
201906 0.009 105.983 0.014
201909 0.012 105.983 0.018
201912 0.008 107.123 0.012
202003 -0.014 109.076 -0.021
202006 0.019 109.402 0.028
202009 0.009 109.320 0.013
202012 -0.019 109.565 -0.028
202103 -0.009 112.658 -0.013
202106 0.002 113.960 0.003
202109 -0.039 115.588 -0.055
202112 -0.023 119.088 -0.031
202203 -0.035 125.031 -0.046
202206 -0.002 131.705 -0.002
202209 -0.053 135.531 -0.064
202212 -0.056 139.113 -0.066
202303 -0.044 145.950 -0.049
202306 0.042 147.009 0.047
202309 -0.030 146.113 -0.033
202312 -0.067 147.741 -0.074
202403 -0.072 149.044 -0.079
202406 -0.035 150.997 -0.038
202409 0.245 153.439 0.260
202412 -0.291 154.660 -0.307
202503 -0.109 157.021 -0.113
202506 -0.143 157.509 -0.148
202509 0.016 158.000 0.017
202512 -0.111 158.320 -0.114
202603 0.708 163.070 0.708

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €0.05 mean?
Celon Pharma (FRA:8RP) has a E10 of €0.05 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Celon Pharma and its competitors.
Is Celon Pharma's E10 too high?
Celon Pharma's current E10 is €0.05. Overall, Celon Pharma has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Celon Pharma's E10 compare to ZTS and UTHR?
Celon Pharma's E10 of €0.05 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Celon Pharma and its competitors. Celon Pharma's current E10 is €0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celon Pharma stock overvalued right now?
Celon Pharma (FRA:8RP) has a current E10 of €0.05. The stock's GF Value™ is €5.11, compared to a current price of €4.39 — trading 14.1% below its estimated fair value. The current E10 is €0.05. Celon Pharma's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Celon Pharma (FRA:8RP), the current E10 is €0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Celon Pharma (FRA:8RP) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of €4.39 is trading 14.1% below its estimated GF Value™ of €5.11.

Key valuation signals for FRA:8RP:

  • E10: €0.05
  • GF Value™: €5.11 vs. price of €4.39 (14.1% below fair value)
  • GF Score™: 13/100 with 3 warning signs

No single metric tells the full story. See the FRA:8RP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Celon Pharma Business Description

Other Exchanges CLN:Poland
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
13GF Score

Get the complete analysis for FRA:8RP

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.39
Price
€5.11
GF Value